Histone deacetylase inhibitor romidepsin enhances anti-tumor effect of erlotinib in non-small cell lung cancer (NSCLC) cell lines.
about
DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines.Amphiregulin promotes resistance to gefitinib in nonsmall cell lung cancer cells by regulating Ku70 acetylation.Histones and lung cancer: Are the histone deacetylases a promising therapeutic target?Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancerLung cancer: Biology and treatment options.Antitumor activity of motesanib alone and in combination with cisplatin or docetaxel in multiple human non-small-cell lung cancer xenograft modelsSilibinin synergizes with histone deacetylase and DNA methyltransferase inhibitors in upregulating E-cadherin expression together with inhibition of migration and invasion of human non-small cell lung cancer cells.Use of class I histone deacetylase inhibitor romidepsin in combination regimensSynergistic antitumor activity of histone deacetylase inhibitors and anti-ErbB3 antibody in NSCLC primary cultures via modulation of ErbB receptors expression.Histone deacetylase inhibitor AR-42 enhances E7-specific CD8⁺ T cell-mediated antitumor immunity induced by therapeutic HPV DNA vaccination.Phase 1 study of romidepsin plus erlotinib in advanced non-small cell lung cancer.Emerging new agents for the management of patients with non-small cell lung cancer.Epigenetics and oncology.Epigenetic alterations in cancer and personalized cancer treatment.Epigenetics in lung cancer diagnosis and therapy.Targeting Chromatin-Mediated Transcriptional Control of Gene Expression in Non-Small Cell Lung Cancer Therapy: Preclinical Rationale and Clinical Results.Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench.Shikonin and its derivatives inhibit the epidermal growth factor receptor signaling and synergistically kill glioblastoma cells in combination with erlotinib.Epigenetic therapy approaches in non-small cell lung cancer: Update and perspectives.Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptide.HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT.Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and PDGFR-β related to anticancer drug resistance.The effect of combined treatment with sodium phenylbutyrate and cisplatin, erlotinib, or gefitinib on resistant NSCLC cells
P2860
Q30931932-697BC909-FCB8-46EF-AB33-D18FE3AA98A0Q33731197-BA358374-21C8-4EBC-BD94-7630C5A1CDC7Q34371189-99053CE6-67EC-4263-88AF-3F88CA26E1D6Q36301182-617EBF1D-CE98-466A-943A-47AF34278DAAQ36328370-E82CAC4E-6BA7-4383-9D5A-835CD2300E48Q36448279-4BF6ED0D-7AF0-4FE7-A6BF-CECBC9001E76Q36776566-1AF1329F-91A5-475F-8C1E-E3C07C75D4EAQ37107439-7BC1EC44-D8EC-49E0-9AE1-F419A4758BD5Q37190106-FEC1E1B8-3C5C-44AE-86A7-96EC639D0270Q37198835-86B70E7E-CABD-4009-8926-2070834C3EAFQ37444619-FF0470CA-C0F6-4FAA-8C9B-988FEFE70560Q38019977-D68F09D5-D9F0-4730-8727-65286C1E1447Q38195260-82CBEB4C-60F0-4D64-AA8F-BDCA0BDD5ABDQ38319591-A5DEC7FF-1E7D-4966-94CC-AB7E8B627D3DQ38457939-4B49727C-D087-4F12-986C-31C5C3D860C5Q38582589-5C12ECC6-CC39-4AF6-AFB3-59A976A159B8Q38745430-7D3F14EF-E396-44B5-9539-8D143878562CQ38908815-488C3616-5D50-46B8-A9C9-0898474ED485Q39009379-99B8EB7C-6BA8-41F1-B833-67E0D707F33BQ39430288-13751559-0F3D-4AC4-BEAA-849A0633B501Q39527047-BEFDE92A-6834-4199-B41E-225DAD0DF68EQ47446128-0566EEB5-4763-49DB-8A89-3A8DE540F1CFQ57816535-37FFE220-8F14-43C7-A6D4-56130340E720
P2860
Histone deacetylase inhibitor romidepsin enhances anti-tumor effect of erlotinib in non-small cell lung cancer (NSCLC) cell lines.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Histone deacetylase inhibitor ...... ung cancer (NSCLC) cell lines.
@en
Histone deacetylase inhibitor ...... in non-small cell lung cancer
@nl
type
label
Histone deacetylase inhibitor ...... ung cancer (NSCLC) cell lines.
@en
Histone deacetylase inhibitor ...... in non-small cell lung cancer
@nl
prefLabel
Histone deacetylase inhibitor ...... ung cancer (NSCLC) cell lines.
@en
Histone deacetylase inhibitor ...... in non-small cell lung cancer
@nl
P2093
P2860
P1476
Histone deacetylase inhibitor ...... ung cancer (NSCLC) cell lines.
@en
P2093
Adi F Gazdar
John D Minna
Junichi Soh
Michael Peyton
P2860
P304
P356
10.1097/JTO.0B013E318194FAE7
P577
2009-02-01T00:00:00Z